688137 近岸蛋白
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.4100.5857.08864.383174.045
总资产报酬率 ROA (%)-0.3880.5556.37443.50381.439
投入资产回报率 ROIC (%)-0.3960.5656.60951.428145.464

边际利润分析
销售毛利率 (%)63.32175.66886.32287.69489.255
营业利润率 (%)-26.7944.25139.64951.76152.375
息税前利润/营业总收入 (%)-54.744-13.88237.41051.92254.110
净利润/营业总收入 (%)-14.9298.38434.29343.58246.178

收益指标分析
经营活动净收益/利润总额(%)103.139159.623102.128108.514105.786
价值变动净收益/利润总额(%)-16.779276.2973.9160.4830.271
营业外收支净额/利润总额(%)3.000-4.6571.215-0.419-0.045

偿债能力分析
流动比率 (X)23.74841.30433.3514.6282.161
速动比率 (X)22.83539.60832.1474.1101.883
资产负债率 (%)6.3194.8035.70929.88340.036
带息债务/全部投入资本 (%)0.9580.6360.6324.39811.233
股东权益/带息债务 (%)10,065.01115,201.72915,250.5371,772.249778.877
股东权益/负债合计 (%)1,482.5881,981.8661,651.570234.639149.778
利息保障倍数 (X)2.0180.774-13.720137.72130.777

营运能力分析
应收账款周转天数 (天)189.114218.365146.60362.97227.313
存货周转天数 (天)673.209782.545568.439239.151285.733